16 results about "Superantigen" patented technology

A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.

A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.

The application discloses a targeting superantigen fusion protein based on an improved SE(3)-Transformer and an implementation method. In an offline stage, amino acid sequences are first converted into one-hot encoding or language model embedding (such as ESM-2), and are spliced with multiple sequence alignment (MSA) features for geometric initialization. A neural network (improved SE(3)-Transformer) combined with multiple sequence alignment (MSA) and an attention mechanism is constructed to predict the coordinates of C alpha, C, N and O atoms for main chain prediction, and the neural network is trained through a gradient descent method based on a physical heuristic potential item. In a verification stage, the improved SE(3)-Transformer after training is used to generate a predicted structure, conformational stability is verified through a simplified force field, and fine tuning is performed based on a confidence score. The application can accurately predict the structure of a target antigen epitope and an antibody variable region, optimize a superantigen functional domain in combination with a graph neural network, and dynamically design a flexible connecting peptide to realize modular fusion.

The present disclosure provides a composition comprising a vaccine conjugate having an SMEZ-2 vector. Also provided are methods for treating cancer comprising administering the vaccine conjugates provided herein.

Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.

The invention relates to the field of biological medicine and immunology, in particular to preparation and application of an anti-staphylococcus aureus enterotoxin B antibody. A heavy chain variable region of the antibody SEB-A8 provided by the invention comprises CDR sequences as shown in SEQ ID NO: 1-3, a light chain variable region of the antibody SEB-A8 comprises CDR sequences as shown in SEQ ID NO: 9-11, and the antibody SEB-A8 has important application value in treatment, prevention or diagnosis of staphylococcus aureus infection. Experimental data show that the antibody can effectively neutralize the superantigen activity of SEB and significantly improve the survival rate of MRSA infected mice, has a dose-dependent protection effect, can be used as a non-antibiotic treatment strategy, is used for treatment of methicillin-resistant staphylococcus aureus infection, has great significance in controlling development of bacterial drug resistance, and has a broad application prospect. And a new research direction is provided for clinical anti-infection treatment.

The present disclosure provides compositions comprising vaccine conjugates with SMEZ-2 carriers. Further provided are methods for treating cancer, comprising administering the vaccine conjugates provided herein. TIFF2025535082000005.tif73148

The invention relates to the technical field of biological pharmacy, and discloses an active super antigen compound biological injection preparation G for treating muscle and joint diseases. The preparation comprises the following components in percentage by mass: 18%-28% of the super antigen compound, 35%-45% of the amino acid mixture and 12%-18% of the bioactive nanoparticle carrier, wherein the super antigen compound accounts for 18%-28% of the total mass of the preparation; the amino acid mixture accounts for 35%-45% of the total mass of the preparation; and the bioactive nanoparticle carrier accounts for 12%-18% of the total mass of the preparation. According to the active super antigen compound biological injection preparation G for treating the muscle and bone joint diseases and the preparation method, a super antigen compound comprises a staphylococcus aureus enterotoxin variant modified by gene engineering and a recombinant human interleukin-1 receptor antagonist fusion protein, and inflammation is reduced without damaging cartilage by precisely regulating and controlling immune response; l-homocysteine and L-hydroxyproline in the amino acid mixture have a synergistic effect, so that not only can free radicals be eliminated, but also cartilage repair and regeneration can be promoted, the problem of cartilage degeneration caused by long-term use of a traditional medicine is effectively solved, and the self-repair capability of tissues is improved.

The invention relates to the technical field of biological injection, and discloses an active super antigen immune activation compound biological injection preparation H. The active super antigen immune activation compound biological injection preparation comprises a drug delivery carrier structure, an immune activation function module and a biological stability guarantee assembly, the drug delivery carrier structure is sequentially composed of temperature response type sustained release microspheres, a serum protease shielding layer and a targeting phospholipid bilayer, and is mediated by a tumor specific navigation system, a tumor microenvironment is accurately anchored, and immune activation is triggered. According to the active super antigen immune activation compound biological injection preparation H and the preparation method thereof, through a three-stage drug delivery system of temperature response microspheres, a targeted phospholipid bilayer and a tumor specificity navigation system, precise targeted drug delivery is achieved, drug enrichment at a tumor part is improved, and through a serum protease shielding layer and a freeze drying protection process, the drug enrichment at the tumor part is improved. The bottleneck that active ingredients are easy to degrade and short in validity period in the prior art is broken through, biological stability is enhanced, and an immune activation window is prolonged.

This invention relates to the fields of biomedicine and immunology, and particularly to the preparation and application of an anti-Staphylococcal enterotoxin B antibody. The antibody provided by this invention has a SEB-A8 heavy chain variable region containing CDR sequences as shown in SEQ ID NO:1-3, and a light chain variable region containing CDR sequences as shown in SEQ ID NO:9-11. It has significant application value in the treatment, prevention, and diagnosis of Staphylococcus aureus infections. Experimental data show that this antibody can effectively neutralize the superantigen activity of SEB, significantly improve the survival rate of MRSA-infected mice, and exhibit a dose-dependent protective effect. It can be used as a "non-antibiotic" treatment strategy for the treatment of methicillin-resistant Staphylococcus aureus infections, which is of great significance in controlling the development of bacterial resistance and provides a new research direction for clinical anti-infective therapy.

The present disclosure relates to pharmaceutical compounds and compositions and methods for treating an allergy and Crohn's disease. Methods for treating an allergy can include (a) predicting potential epitopes based proteomes of microbiome and that of an allergen, (b) filtering the potential epitopes obtained in step a) to result in a list of epitopes; and (c) reengineering the list of epitopes obtained in step b) to result in the new epitope. Methods for treating Crohn's disease can include (a), identifying one or more binding regions of an HLA class II protein and / or hemagglutinin to I2 superantigen; (b) determining a first peptide sequence corresponding to the one or more binding regions, and (c) producing a peptide inhibitor having a second peptide sequence that is a mutation of the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.

The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.

The invention relates to the technical field of biological preparations, and discloses a preparation method of an active super antigen compound biological injection preparation for pain repair T. The preparation method comprises the following steps: extracting a super antigen with relatively high activity on the basis of culturing a staphylococcus aureus strain; based on amplification expression of a target cytokine gene and submaxillary gland cell treatment, collecting a cytokine IL-10 and a nerve growth factor NGF, and mixing the extracted active super antigen, the cytokine IL-10, the nerve growth factor NGF, an NSAIDs derivative and an amino acid group in sequence. According to the active super antigen compound biological injection preparation pain repairing T and the preparation method thereof, a multi-target synergistic effect mechanism is formed by adopting a compound combination of an active super antigen, IL-10, NGF, an NSAIDs derivative, glutathione and taurine, so that the super antigen activates immune regulation, IL-10 inhibits inflammation, NGF promotes nerve repairing, and NSAIDs provides anti-inflammatory and analgesic effects; meanwhile, an amino acid group is matched to enhance the oxidation resistance, so that the action mechanism of pain repair is effectively improved.

The invention relates to an active super antigen compound biological injection preparation NF for treating male and female dysfunctions and a preparation method thereof, and the compound biological injection preparation NF comprises a general basic formula NF, male NF-M and female NF-F, the general basic formula NF comprises the following components and parameters: 0.1 to 0.5 mg / mL of super antigen mutant, 50 to 100 [mu] g / mL of neurotrophic factor, 10 to 20 [mu] g / mL of hormone regulating peptide and 8 to 10 mg / mL of pH-responsive lipid nanoparticles. According to the active super antigen compound biological injection preparation NF for treating male and female dysfunctions and the preparation method, by activating TCR-V beta chains on the surfaces of T cells and MHC-II molecules of APC, local immune regulation instead of systemic inflammatory reaction is induced, the microcirculation and neuroendocrine functions of a reproductive system are improved in a targeted manner, and the effect of treating male and female dysfunctions is achieved. Superantigen is adopted to activate local immune cells to secrete vascular endothelial growth factors and NO, blood perfusion is improved, neurotrophic factors repair cavernous nerve injury, hormone regulating peptides indirectly regulate the sex hormone level through hypothalamus-pituitary-gonad axis, and the composition is suitable for hormone-related dysfunction.

The invention refers to a split superantigen, divided into two fragments that by itself do not exhibit biologic activity, only upon dimerization they regain T cell activity. Scope of the invention is a screening method for detection of effective split superantigen designs, where split superantigen fragments are fused with coiled-coil forming peptides. The present invention relates to the field of cancer immunology. Each split superantigen fragment is fused with antibody or other tumor antigen specific protein, therefore only upon the binding of split superantigen-antibody fusion proteins to the tumor antigen, split superatigen fragments comes to proximity and reconstitute into biologically active form that activates T-cell response.